Trim 20-25% ISRG exposure in $410-415 zone, reducing allocation from 3.5% to 2.5-2.8%, anchored by 50 SMA stop at $376
The Underweight survives at modest magnitude that respects both binding lessons: 20-25% trim captures macro premium while preserving the compounding franchise—meaningful enough to exceed 9/21's 75% benchmark retention threshold (avoiding zero-alpha collapse), yet modest enough to respect 9/28's sideways-chop-as-base-case lesson (avoiding overcommitment against a chart that doesn't support directional payoff). The 50 SMA at $376 anchors residual defense, not the trader's $350 stop. Quality floor remains intact: Q2 revenue +18.5% YoY, gross margin 67.8%, operating margin 33.6%, FCF +69% YoY at $948M, $5.2B cash against zero LT debt.
| Position | Action |
|---|---|
| Current overweight position at ~3.5% allocation | Trim 20-25% of ISRG exposure in $410-415 zone, reducing portfolio allocation to approximately 2.5-2.8% |
| Operating window constraint | Maintain 70-75% benchmark retention to avoid 9/21's zero-alpha trap at 75-80% retention |
| Base case is sideways chop near resistance (not directional bear payoff) | Avoid 30-40% aggressive trim as overcommitting against chart that doesn't support directional payoff |
Intuitive Surgical is the highest-quality compounder in medical technology, currently trading at a 31% discount to its 52-week high, with bullish momentum reasserting, a fortress balance sheet, accelerating fundamentals, and a structural buyback floor — all while the bear narrative relies almost entirely on macro timing rather than business deterioration.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 399.56 | bullish |
| 50 SMA | 376.50 | bullish |
| 200 SMA | 449.46 | bearish |
| RSI (14) | 67.21 | bullish |
| MACD | 9.03 | bullish |
| MACD Signal | 4.98 | bullish |
| MACD Histogram | +4.05 | bullish |
| Bollinger Middle Band (20 SMA) | 382.93 | neutral |
| Bollinger Upper Band | 421.75 | neutral |
| Bollinger Lower Band | 344.12 | neutral |
| ATR (14) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
The PEG of 1.93 on a business compounding net income at 29% is reasonable, especially considering quality premium and understated growth
↩ rebuts: “Bear's 47.3x P/E and 'multiple compression' framing”
EV: $540 base case, $620 bull case, $603.88 52-week high reclaim · concedes: The business is extraordinary — the bear does not dispute fundamental acceleration; The 30-year yield is at multi-decade highs and the probability of Fed cuts in 2026 is low (96% probability of zero cuts); The 200 SMA does represent overhead resistance; Rallies against the 200 SMA can fail in isolation
ISRG's recent sequential deceleration, intact death cross with 200 SMA overhead, premium valuation with high beta, worsening macro headwinds, and intensifying competitive threats create asymmetric risk/reward favoring a SELL, with bear targets of $370/$330/$280 versus bull targets requiring a hockey-stick reacceleration the data contradicts.
EV: -$7.1% probability-weighted (bear case) · concedes: ISRG is a great business with strong procedure volume and clinical outcomes; No competitor has demonstrated the full ecosystem maturity to threaten ISRG dominance in the near term; da Vinci remains the dominant surgical robotics platform globally; Buybacks do provide some offset to dilution and reduce share count; Current price ($412) is well below 52-week high ($603.88); ATR compression could theoretically precede expansion in either direction
→ vs conservative: Anchor bias; love affair with fundamentals ignores regime transition; fortress balance sheet didn't prevent 45% decline; quality doesn't protect from multiple compression
→ vs neutral: Wishy-washy positioning gets worst of both worlds; waiting for Q3 earnings is waiting for a 7% sequential EPS step-up that sequential data contradicts; waiting for 200 SMA test at $449 where everyone will sell
| 11.27 |
| neutral |
| Close | 412.18 | neutral |
| Volume | 1,878,125 | neutral |
Support: 399.56 · 382.93 · 376.5 · 350.16 · 332.02 | Resistance: 414.79 · 421.75 · 449.46
ISRG exhibits a constructive short-term recovery setup with price (412.18) trading above the 10 EMA (399.56) and 50 SMA (376.50), while MACD's bullish crossover and expanding histogram confirm momentum re-acceleration. The RSI at 67.21 remains below overbought territory but shows limited upside runway before reaching the 70 threshold. The dominant long-term headwind remains the declining 200 SMA at 449.46, which has not been reclaimed; a weekly close above this level would be required to flip the secular trend bullish. Near-term support sits at 399.56 (10 EMA) with a critical invalidation level at the September 8 swing low of 350.16.
Market Cap
$147.7 B
Share Price
~$417
52-Week High
$603.88
52-Week Low
$328.57
50-Day Moving Avg
$375.32
200-Day Moving Avg
$450.18
Beta
1.465
P/E (TTM)
47.3x
Forward P/E
34.1x
PEG Ratio
1.93
P/B
8.03x
EPS (TTM)
$8.71
Forward EPS
$12.09
Revenue CAGR 2022-2025
+17.4%
Net Income CAGR 2022-2025
+29.4%
FCF CAGR 2022-2025
+37.6%
Gross Margin (TTM)
~66.7%
Operating Margin (TTM)
33.6%
Net Margin (TTM)
28.4%
EBITDA Margin (TTM)
~37.9%
ROE
17.4%
ROA
10.5%
Operating CF (TTM)
~$3.7 B
Free Cash Flow (TTM)
$2.62 B
FCF Margin
23.7%
Cash + ST Investments (Q2 2026)
$5.22 B
Total Debt
~$0 (effectively debt-free)
Net Cash Position
~$5 B+
Current Ratio
4.96x
Total Equity
$18.17 B
FY2025 Buybacks
$2.30 B
Q1 2026 Buybacks
$1.12 B
Dividend
None (buyback-only)
Q2 2026 Revenue
$2,892 M
Q2 2026 Operating Income
$972 M
Q2 2026 Net Income
$818 M
Q2 2026 Diluted EPS
$2.29
Q2 2026 Free Cash Flow
$948 M
FY2025 Revenue
$10,064.7 M
FY2025 Net Income
$2,856.0 M
FY2025 EBITDA
$3,622.6 M
FY2025 FCF
$2,490.7 M
Installed Base
>10,000 da Vinci systems globally
R&D Spend (Q2 2026)
$370.6 M
SBC (Quarterly)
~$209 M (~$830M annualized)
Strengths
Concerns
ISRG is the dominant global leader in robotic-assisted minimally invasive surgery with a fortress balance sheet ($5B+ net cash, zero debt) and exceptional cash generation ($2.62B TTM FCF). The company has demonstrated multi-year acceleration with 17.4% revenue CAGR and 29.4% net income CAGR from 2022-2025, driven by its high-margin razor-and-blade business model and expanding margins (now 33.6% operating). However, the stock trades at a demanding 47.3x P/E (34.1x forward) with elevated beta of 1.465, leaving limited margin of safety; the bear case centers entirely on multiple compression risk while the bull case depends on continued category expansion (Ion, da Vinci 5) and AI/digital ecosystem monetization justifying the premium.
Macro: Hawkish duration regime: 30-year Treasury at highest level since 2002, mortgage rates at 7.58% near 3-year high. Prediction markets price zero Fed cuts in 2026 at 96% probability ($8.7M traded volume). US recession probability at 8% (low conviction). Gold at $4,147.70 (+0.27%) reinforcing hedged duration risk. Equities wavering with Dow, S&P 500, and Nasdaq lower on rising yields. Markets digesting rather than panic-selling, suggesting macro stress without imminent recession.